Posted inClinical Updates HIV/AIDS Infectious Diseases news
Long-Acting Injectable Cabotegravir-Rilpivirine Every 8 Weeks for Adolescents with HIV in Sub-Saharan Africa: Evidence from the LATA Trial and Contemporary Context
The LATA trial demonstrates that long-acting injectable cabotegravir-rilpivirine given every 8 weeks is superior to daily oral ART for maintaining virological suppression in adolescents with HIV in sub-Saharan Africa, with a favorable safety and acceptability profile, heralding a transformative option for this vulnerable population.